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Distributional Impact Of Rotavirus Vaccination In 25 
GAVI Countries: Estimating Disparities In Benefits 
And Cost Effectiveness
By: Richard Rheingans, Deborah Atherly & John Anderson 
Abstract
Background: Other studies have demonstrated that the impact and cost effectiveness of rotavirus 
vacci-nation differs among countries, with greater mortality reduction benefits and lower cost-
effectiveness ratios in low-income and high-mortality countries. This analysis combines the results of 
a country level model of rotavirus vaccination published elsewhere with data from Demographic and 
Health Surveys on within-country patterns of vaccine coverage and diarrhea mortality risk factors to 
estimate within-country distributional effects of rotavirus vaccination. The study examined 25 
countries eligible for funding through the GAVI Alliance.
Methods: For each country we estimate the benefits and cost-effectiveness of vaccination for each 
wealth quintile assuming current vaccination patterns and for a scenario where vaccine coverage is 
equalized to the highest quintile’s coverage. In the case of India, variations in coverage and risk 
proxies by state were modeled to estimate geographic distributional effects.
Results: In all countries, rates of vaccination were highest and risks of mortality were lowest in the 
top two wealth quintiles. However countries differ greatly in the relative inequities in these two 
underlying variables. Similarly, in all countries examined, the cost-effectiveness ratio for vaccination 
($/Disability-Adjusted Life Year averted, DALY) is substantially greater in the higher quintiles 
(ranging from 2–10 times higher). In all countries, the greatest potential benefit of vaccination was in 
the poorest quintiles. However, due to reduced vaccination coverage, projected benefits for these 
quintiles were often lower. Equitable coverage was estimated to result in an 89% increase in mortality 
reduction for the poorest quintile and a 38% increase overall.
Conclusions: Rotavirus vaccination is most cost-effective in low-income groups and regions. 
However in many countries, simply adding new vaccines to existing systems targets investments to 
higher income children, due to disparities in vaccination coverage. Maximizing health benefits for 
the poorest children and value for money require increased attention to these distributional effects.
Richard Rheingans, Deborah Atherly & John Anderson (2012) "Distributional Impact Of Rotavirus Vaccination In 
25 GAVI Countries: Estimating Disparities In Benefits And Cost Effectiveness" Vaccine A15-A23 Version of 
Record Available From (www.researchgate.net)
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monstrates that the impact and cost-effectiveness of vac-
nation is heterogeneous [1–4]. In general there are greater 
nefits and better cost-effectiveness ratios in low-income coun-
ies and regions, primarily due to higher estimated mortality. At 
e same time, lower vaccination coverage, along with reduced 
ficacy and great delays in timing mean that the percent reduc-
on in rotavirus burden would be lowest in these countries 
].
However this global pattern of disparities is likely to be repeated 
ithin as well as between countries [6]. Poorer households and 
oorer regions within a particular country are likely to have high 
iarrhea mortality risk and lower levels of timely vaccination cover-
e. This suggests that distribution of the benefit, cost-effectiveness 
d residual (post-vaccination) rotavirus mortality are also likely 
 differ after vaccine introduction.
This paper estimates the geographic and socio-economic distri-
utional effects of rotavirus vaccine introduction within a subset
f countries eligible for funding by the GAVI Alliance. This includes
he distribution of benefits, cost-effectiveness, and residual (post-
accine introduction) mortality risk. The main research question
‘how do outcomes differ across geographic and socio-economic
radients at the regional, national, and sub-national scales?’ Bet-
er understanding of distributional effects is essential in tackling
he substantial remaining rotavirus mortality burden, even with
v
s
G
t
a
a
d
t
s
n
B
i
l
v
t
t
c
l
g
b
t
a
I
s
c
m
e
H
o
a
i
e
o
e
e
s
e
a
a
i
2
2
e
d
i
r
u
p
s
o
d
a
t
T
0
a
Table 1
Selected Demographic and Health Survey (DHS) country data for the distributional
impacts of rotavirus vaccination.
Country by DHS region Year
Latin America and Caribbean
Haiti 2006
South and Southeast Asia
Bangladesh 2007
Cambodia 2005
India 2006
Nepal 2006
Sub-Saharan Africa
Burkina Faso 2003
Cameroon 2004
Chad 2004
Dem. Rep. of Congo 2007
Ethiopia 2005
Ghana 2008
Guinea 2005
Kenya 2009
Lesotho 2004
Liberia 2007
Malawi 2004
Mali 2006
Mozambique 2003
Niger 2006
Nigeria 2008
Senegal 2005
Sierra Leone 2008
Tanzania 2005accination. Distributional effects also have implications for deci-
ions about where to invest first, even among and within
AVI-eligible countries.
Best practices for economic evaluations of health interven-
ions typically require distributional analyses to assess who within
population is more or less likely to benefit. This is based on
n understanding that cost-effectiveness is just one criterion in
ecision-making and other factors, such as who benefits, also need
o be considered. While in practice, few vaccine cost-effectiveness
tudies directly explore these issues, there is evidence that vacci-
ation can have both pro-poor and anti-poor distributional effects.
ishai et al. demonstrated that near universal measles vaccination
n Bangladesh reduced disparities in under-5 mortality [7]. Michae-
idis et al. found that efforts in reducing disparities in influenza
accination among elderly minority groups in the US was moderate
o highly cost-effective [8]. Human papillomavirus (HPV) vaccina-
ion provides a somewhat different scenario. While the burden of
ervical cancer is disproportionately borne by poorer women with
imited access to prevention and timely treatment, vaccination pro-
rams may similarly miss the target population [9,10].
Several approaches have been suggested for addressing distri-
utional and equity concerns in cost-effectiveness. One approach is
o explicitly weight outcomes among the poor as higher than those
mong better off sub-populations through an equity weight [11,12].
n some cases, weights are suggested based on socio-economic
tatus and in other contexts based on the severity of individual
onditions [13].
In some contexts there is an equity-efficiency tradeoff where the
ost impactful or efficient is not the most equitable [14]. Walensky
t al. modeled a variety of prevention and treatment approaches for
IV in South Africa, considering the cost-effectiveness and equity
f different intervention combinations [15]. Their model included
calculation of the opportunity cost of equity, based on the health
mprovements that would be forgone in order to select the most
quitable solutions. Jehu-Appiah et al. demonstrated the usefulness
f a similar modeling approach to quantify the trade-offs between
fficiency and equity in health investment priorities in Ghana [16].
One of the simplest approaches to assessing distributional
ffects is to explicitly estimate costs and impacts for distinct
ub-populations. This may include stratifying by age, sex, socio-
conomic status and/or geographic regions. Coyle et al. provide
general framework for population stratified cost-effectiveness
nalysis [17] and Sculpher describes the application of the approach
n contexts such as the UK’s NICE evaluation process [18].
. Methods
.1. General model structure
We used an existing country-level rotavirus impact and cost-
ffectiveness model [1] that has been updated with newly available
ata [5]. Estimates here are for vaccinating a single birth cohort,
ncluding outcomes during their first five years of life. National
otavirus mortality estimates were based on recently published fig-
res [19]. Estimates of inpatient and outpatient visits are also from
reviously published studies [20].
Vaccine efficacy estimates were based on region and mortality
trata [21–23]. Estimates for high mortality countries were based
n pooled estimates from recent trials [21] and are described in full
etail in Atherly et al. [5]. Efficacy was adjusted for the expected
ge at which first and second dose would be received in each coun-
ry, based on DPT1 and DPT2 coverage from DHS surveys [3,24].
his was done by modeling coverage of 1 and 2 doses of vaccine at
–2, 3–5, 6–8 and 9–11 months. Reported DPT1 and DPT2 coverage
mong 12–23 month old children was used to estimate the fractionUganda 2006
Zambia 2007
of those that would receive each vaccine at the different age ranges
[5]. Vaccination effectiveness was based on the fraction of children
at each age with 0, 1, or 2 doses and the expected protection of each,
assuming 50% lower efficacy for a single dose in the 2-dose regime.
For each age band, the effectiveness was applied to the proportion
of rotavirus deaths that would occur during that period. Current
SAGE recommendations suggest that children over 8 months or 32
weeks not receive a vaccine in order to avoid potential adverse
effects. The model used in this study assumes that children receiv-
ing their second DPT dose between 8 and 12 months of age would
still receive it [25].
Medical treatment costs were estimated for inpatient and out-
patient visits, using cost-estimates from WHO-CHOICE for facility
charges and extrapolations of medication and diagnostic costs from
published studies, as described elsewhere [1,3]. Medical costs were
in 2010 US Dollars and presented in more detail elsewhere [5]. All
costs and DALY estimates were discounted at 3%. Cost-effectiveness
estimates are based on a two-dose vaccine with a price of $2.50 per
dose.
In the original model we adjusted for a potential differential
coverage among children likely to suffer rotavirus mortality [1].
For the current model we eliminated that assumption since we are
explicitly modeling the co-distribution of risks and access.
2.2. Socio-economic distribution of immunization benefits at the
national level
The distributional impact of vaccination in a given country
was modeled by incorporating data on the disparities in vaccine
coverage by wealth quintile at the national level and by estimat-
ing the distribution of rotavirus mortality risk by wealth quintile.
Both of these were estimated using available data (2003 or later)
from the most recent Demographic and Health Surveys of the 25
GAVI-eligible countries [26]. Countries were selected based on the
availability of data at the time of the analysis. Countries with earlier
surveys were excluded given that disparities may change over time
due to ongoing efforts to achieve universal coverage. Table 1 shows
Table 2
Selected inputs for estimating the distributional impacts and cost effectiveness of
rotavirus vaccination.
Variable Value Reference
Health
Rotavirus mortality Country-
specific
[19]
Hospitalization 0.016 [20]
Distribution of rotavirus mortality by
wealth and region
Country-
specific
Based on [26]
Vaccination
Vaccine efficacy
Severe rotavirus
High mortality countries 0.57 [5]
Mid-low mortality countries in Asia 0.72 [5]
Latin America and Europe 0.85 [23]
Outpatient visit
High mortality countries 0.47 [5]
Mid-low mortality countries in Asia 0.70 [5]
Latin America and Europe 0.78 [23]
Sub-national vaccination coverage Country-
specific
[26]
Costs
Hospitalization $17–232 [5]
Outpatient visit $1–13 [5]
Vaccination system cost $0.50–1.26 [5]
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Vaccine price ($/dose) $2.50 Authors
assumption
he countries and the year of the survey. For immunization cover-
ge, DPT2 coverage was used as a proxy to estimate the distribution
f rotavirus vaccination by quintile.
No specific publications were identified with data on the distri-
ution of rotavirus or diarrheal mortality by wealth quintile. As a
esult, we used alternative proxy measures to estimate the poten-
ial distribution of rotavirus mortality across wealth quintiles. We
sed three proxy measures: post-neonatal infant mortality, less
han −2 standard deviations in weight for age Z-scores, and less
han −3 standard deviations in weight for age Z-scores [26]. The
rst of these was expected to correlate with rotavirus mortality risk
s a proxy for health care access, while the latter two were expected
o be proxies for physical susceptibility due to their demonstrated
ssociation with diarrheal mortality [27]. Post-neonatal infant mor-
ality (between 1 and 11 months of age) was used since it closely
orresponds with the primary ages of rotavirus mortality. However
t is unclear whether other measures like 1–59 months mortality
ould be a more appropriate proxy. The rates of low weight for
ge and post-neonatal infant mortality by quintile were used to
stimate the fraction of each outcome that would occur in a given
uintile. For each of these proxies, the quintile fraction was applied
o the estimated national annual rotavirus deaths to estimate the
otavirus deaths for each quintile. Given the uncertainty as to which
roxy would best estimate the distribution, the average of the esti-
ated deaths based on the three proxies were averaged for each
uintile, resulting in a single estimate of rotavirus mortality that
ould occur in each quintile. In addition, we also used each of
he proxy measures to conduct a sensitivity analysis of the main
utcomes. These are shown as a range in Table 4. Overall model
arameters are shown in Table 2 and key inputs for the distribu-
ional analysis are shown in Table 3.
Using these estimates of vaccination and mortality distribu-
ion for each country, we estimated children vaccinated, rotavirus
eaths averted, DALYs averted, net costs and cost-effectiveness by
ealth quintile..3. Geographic distribution of benefits
Socio-economic and geographic disparities in health and inter-
ention impact may be highly correlated at the sub-national level,Fig. 1. Estimated vaccination coverage and under-5 rotavirus mortality by wealth
quintile in 8 high mortality countries, based on DHS surveys.
in part due to the geographic clustering of socio-economic char-
acteristics such as wealth and education. In order to explore this,
we also estimated the geographical distribution of rotavirus vac-
cination effects for one country – India. Esposito et al. developed
a national model of rotavirus introduction and estimated the ben-
efit and cost-effectiveness for India. They estimate that rotavirus
vaccination could prevent about one-third of rotavirus-associated
deaths in India, suggesting that improving current vaccine coverage
would significantly increase vaccination impact [28]. This model
includes estimates of rotavirus mortality and vaccination coverage
by state from DHS data [26] using the same method as described
above for wealth quintiles.
2.4. Characterizing disparities in risk and benefit
In order to characterize and compare the distribution of key out-
comes at the national level, we developed concentration curves and
concentration indices [29]. For a given outcome, the concentration
curve graphs the fraction of that outcome that occurs within differ-
ent fractions of the population ranked by wealth; for example, the
portion of national vaccinations occurring in the bottom 10, 20, and
50 percent of the population ranked by wealth. The concentration
index is a single dimensional number between −1 and 1 that rep-
resents the extent to which the concentration curve of an outcome
differs from the line of equity where the bottom x percent of the
population accounts for x percent of the outcomes.
2.5. Impact of alternative scaling strategies on benefit and
cost-effectiveness
We estimated the health cost due to disparities in vaccination
between wealth quintiles within each country by modeling a sce-
nario in which vaccination rates in all quintiles are equal to that of
the quintile with the highest coverage.
3. ResultsDetailed information is presented for the 8 countries with the
highest rotavirus mortality estimates and available distributional
data from DHS. Fig. 1 shows the estimated co-distribution of
Table 3
Distributional analysis country-level input values.
Country wealth
quintile
DPT2 coverage
(%)
Post-neonatal
infant mortality
Weight for age
(< − 2 SD)
Weight for age
(< −3 SD)
Rotavirus deaths/1000
births
Bangladesh 94.4 17.4 42.2 10.7 2.25
Poorest 92.9 17.7 50.7 16.8 2.84
2nd 90.8 23.4 45.1 13.0 2.72
Middle 94.5 23.3 46.0 10.9 2.58
4th 97.2 13.5 40.9 7.1 1.80
Richest 96.8 9.0 28.1 5.7 1.29
DR Congo 60.6 53.7 27.3 6.7 11.85
Poorest 42.7 69.6 32.0 6.0 13.30
2nd 50.6 61.6 30.3 6.8 12.94
Middle 57.8 54.2 30.1 8.3 13.26
4th 68.6 51.6 25.1 8.3 12.34
Richest 83.5 31.6 19.1 3.9 7.40
Ethiopia 48.1 39.2 34.9 10.6 7.70
Poorest 37.2 40.8 39.8 13.2 8.80
2nd 44.9 47.4 41.1 17.2 10.30
Middle 45.0 38.5 35.9 10.4 7.69
4th 50.6 39.5 32.5 6.9 6.65
Richest 62.9 29.8 25.4 5.1 5.06
India 69.1 19.2 43.8 14.4 3.81
Poorest 46.9 26.2 60.1 25.5 5.72
2nd 59.3 24.8 52.9 19.6 4.89
Middle 70.5 21.1 44.3 13.2 3.84
4th 79.3 15.2 36.9 9.2 2.88
Richest 89.3 8.9 24.6 4.5 1.70
Kenya 93.3 26.0 18.8 3.7 9.44
Poorest 88.5 26.3 27.9 6.5 13.43
2nd 92.6 31.0 21.7 5.5 12.10
Middle 94.9 26.9 20.9 2.5 8.91
4th 96.3 17.9 12.6 2.9 6.76
Richest 94.3 27.7 10.7 1.0 6.01
Niger 49.1 50.9 42.8 16.6 10.77
Poorest 38.3 47.6 46.1 20.5 11.66
2nd 48.4 54.3 47.7 17.7 11.66
Middle 40.7 55.1 45.4 20.2 12.07
4th 46.0 60.5 45.1 16.8 11.69
Richest 72.2 37.2 29.8 7.6 6.77
Nigeria 47.4 39.1 27.4 9.9 12.17
Poorest 14.9 49.4 40.5 17.9 18.48
2nd 30.2 52.0 35.1 13.6 16.18
Middle 43.8 40.5 26.9 9.0 11.88
4th 64.7 33.9 21.7 6.1 9.24
Richest 83.5 19.6 13.0 2.7 5.07
Uganda 80.8 52.4 15.6 4.1 8.05
Poorest 79.4 68.0 20.6 5.5 10.61
2nd 80.3 59.0 15.6 3.3 7.85
Middle 82.2 54.0 17.0 4.2 8.42
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4th 81.7 49.0
Richest 80.4 32.0
nder-5 rotavirus mortality and vaccination coverage by wealth
uintile for 8 countries. Each line represents a different country and
ach point in the line represents one wealth quintile in that country.
n general coverage was highest and mortality lowest in the rich-
st quintile. However countries varied in the relative disparities for
ach of the variables.
Fig. 2 shows the benefits (under-5 rotavirus deaths averted per
000 births) and cost-effectiveness ratio (CER, $/DALY) associated
ith rotavirus vaccination for each wealth quintile within the 8
ountries. Each point in the figure represents a different quintile.
n most countries, the CER is highest (least cost-effective) for the
ichest quintile and the benefit is the lowest, primarily due to lower
stimated mortality rates. In poorer quintiles, the benefit tends to
o up due to increased mortality, but sometimes goes down due to
ower vaccination coverage rates.
Estimates of benefits and cost-effectiveness for the selected
countries are shown in Table 4. Detailed information for all
5 countries can be found at the website for the model (http://
gh.phhp.ufl.edu/distributional-effects-of-rotavirus-vaccination/).
n all countries, the incremental cost-effectiveness ratio was least16.5 6.1 9.32
8.4 1.5 4.06
favorable in the richest quintiles. The largest relative differences in
the CERs were in Cameroon, India, Nigeria, Senegal, and Mozam-
bique, where the CER in the richest quintile was 355%, 273%, 265%,
253%, and 227% higher than in the poorest. The differences were
lowest in Zambia, Chad, Burkina Faso, Liberia, and Niger (all less
than 75% higher).
In addition to the analysis using combined indicators of relative
rotavirus mortality, separate analyses were run using each of the
individual indicators: post-neonatal infant mortality, less than −2
Z-score weight for age, and less than −3 Z-score weight for age.
The results of these analyses are shown in Table 4 as the range for
each outcome. While patterns differed slightly between countries,
all three of the individual indicators produced consistent results.
The analysis using less than −3 Z-score resulted in the strongest
equity effects.
Fig. 3 shows the relationship between disparities in input
variables (vaccine coverage and mortality) and output variables
(benefit and post-vaccination mortality). The figure uses Concen-
tration Index (CI) data on each variable for each country to do this.
CI values that are negative are concentrated in the poor and those
Table 4
Estimated distributional effects of rotavirus vaccination – mortality reduction and cost-effectiveness in selected GAVI-eligible countries.
Country wealth
quintile
Rotavirus deaths averted CER ($/DALY) Rotavirus deaths
averted/1000 births
Equity scenario –
deaths averted/1000
births
Health cost of disparity
(rotavirus deaths not
averted)
Range Range Range Range Range
Bangladesh 4084 $140.38 0.98 1.01 143 (132–151)
Poorest 1014 (818–1261) $111.00 (89–138) 1.22 (0.99–1.52) 1.28 (1.03–1.59) 47 (38–58)
2nd 950 (840–1057) $115.89 (104–131) 1.14 (1.01–1.27) 1.23 (1.08–1.36) 67 (59–74)
Middle 939 (832–1095) $121.95 (105–138) 1.13 (1–1.32) 1.16 (1.03–1.36) 27 (24–31)
4th 675 (558–815) $174.57 (145–211) 0.81 (0.67–0.98) 0.81 (0.67–0.98) 0 (0–0)
Richest 479 (433–558) $245.06 (210–271) 0.58 (0.52–0.67) 0.58 (0.52–0.67) 2 (2–2)
DR Congo 9970 $28.20 3.22 4.44 4146 (3978–4303)
Poorest 1577 (1265–1820) $25.09 (22–31) 2.55 (2.04–2.94) 4.98 (4–5.75) 1507 (1209–1739)
2nd 1818 (1699–1908) $25.79 (25–28) 2.94 (2.75–3.08) 4.85 (4.53–5.09) 1182 (1105–1241)
Middle 2128 (1918–2369) $25.17 (23–28) 3.44 (3.1–3.83) 4.97 (4.48–5.53) 946 (853–1053)
4th 2351 (2073–2812) $27.03 (23–31) 3.80 (3.35–4.54) 4.62 (4.08–5.53) 511 (450–611)
Richest 1715 (1608–1920) $45.11 (40–48) 2.77 (2.6–3.1) 2.77 (2.6–3.1) 0 (0–0)
Ethiopia 5655 $43.38 1.66 2.17 1929 (1845–2048)
Poorest 1001 (910–1093) $37.89 (35–42) 1.47 (1.34–1.61) 2.49 (2.26–2.72) 691 (629–755)
2nd 1414 (1242–1719) $32.37 (27–37) 2.08 (1.83–2.53) 2.91 (2.56–3.54) 567 (498–689)
Middle 1057 (1039–1087) $43.40 (42–44) 1.55 (1.53–1.6) 2.17 (2.14–2.23) 420 (413–432)
4th 1029 (777–1199) $50.15 (43–66) 1.51 (1.14–1.76) 1.88 (1.42–2.19) 250 (189–291)
Richest 972 (714–1124) $65.96 (57–90) 1.43 (1.05–1.65) 1.43 (1.05–1.65) 0 (0–0)
India 34,616 $82.98 1.20 1.55 12,917 (12,218–13,979)
Poorest 7064 (6398–8320) $55.22 (47–61) 1.22 (1.11–1.44) 2.33 (2.11–2.74) 6386 (5784–7522)
2nd 7649 (7181–8086) $64.48 (61–69) 1.32 (1.24–1.4) 1.99 (1.87–2.11) 3870 (3633–4091)
Middle 7130 (6474–7745) $82.24 (76–90) 1.23 (1.12–1.34) 1.56 (1.42–1.7) 1901 (1726–2065)
4th 6023 (5075–6699) $109.51 (98–130) 1.04 (0.88–1.16) 1.17 (0.99–1.31) 759 (640–845)
Richest 3992 (2796–5029) $186.07 (148–265) 0.69 (0.48–0.87) 0.69 (0.48–0.87) 0 (0–0)
Kenya 5802 $35.38 3.95 4.07 229 (197–258)
Poorest 1566 (1113–1940) $24.90 (20–35) 5.32 (3.79–6.61) 5.79 (4.13–7.19) 138 (98–171)
2nd 1476 (1329–1718) $27.62 (24–31) 5.02 (4.53–5.85) 5.22 (4.71–6.09) 59 (53–69)
Middle 1113 (800–1312) $37.54 (32–52) 3.79 (2.73–4.47) 3.84 (2.77–4.54) 16 (12–19)
4th 858 (803–942) $49.42 (45–53) 2.92 (2.74–3.21) 2.92 (2.74–3.21) 0 (0–0)
Richest 746 (318–1249) $55.64 (33–130) 2.54 (1.08–4.26) 2.59 (1.11–4.35) 16 (7–26)
Niger 1934 $31.97 2.37 3.48 995 (961–1041)
Poorest 327 (281–373) $29.54 (26–34) 2.00 (1.73–2.29) 3.77 (3.25–4.31) 290 (249–330)
2nd 413 (406–424) $29.55 (29–30) 2.53 (2.49–2.6) 3.77 (3.71–3.88) 203 (199–208)
Middle 360 (339–390) $28.55 (26–30) 2.20 (2.08–2.39) 3.90 (3.69–4.25) 278 (263–302)
4th 394 (367–429) $29.48 (27–32) 2.41 (2.25–2.64) 3.78 (3.53–4.14) 224 (209–245)
Richest 358 (260–414) $50.92 (44–70) 2.19 (1.6–2.54) 2.19 (1.6–2.54) 0 (0–0)
Nigeria 15,300 $28.30 2.59 4.56 14,705 (13,893–15,885)
Poorest 1459 (1217–1747) $18.60 (16–22) 1.24 (1.03–1.48) 6.93 (5.77–8.29) 6716 (5601–8044)
2nd 2589 (2495–2691) $21.24 (20–22) 2.19 (2.11–2.28) 6.07 (5.84–6.3) 4570 (4404–4749)
Middle 2758 (2582–2932) $28.92 (27–31) 2.34 (2.19–2.48) 4.46 (4.17–4.73) 2499 (2341–2658)
4th 3166 (2585–3625) $37.20 (33–46) 2.68 (2.19–3.07) 3.46 (2.82–3.96) 920 (751–1053)
Richest 2242 (1477–2705) $67.82 (56–103) 1.90 (1.25–2.29) 1.90 (1.25–2.29) 0 (0–0)
Uganda 3935 $41.48 2.92 2.97 62 (65–71)
Poorest 1017 (1002–1031) $31.51 (31–32) 3.77 (3.72–3.82) 3.91 (3.85–3.96) 32 (35–36)
2nd 762 (625–879) $42.55 (37–52) 2.83 (2.32–3.26) 2.89 (2.38–3.34) 16 (15–21)
Middle 836 (815–870) $39.67 (38–41) 3.10 (3.02–3.23) 3.10 (3.02–3.23) 0 (0–0)
4th 920 (743–1176) $35.86 (28–44) 3.41 (2.76–4.36) 3.43 (2.77–4.39) 5 (5–7)
1.46
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Richest 394 (285–477) $82.31 (68–114)
ote: National level results reflect the results without adjusting for distributional e
hat are positive are concentrated in the rich. The absolute value of
he CI reflects the degree of disparity (values close to 1 and −1 are
ore inequitable).
Fig. 3a shows the concentration of pre- and post-vaccination
otavirus mortality on the two axes. Pre- and post-vaccination mor-
ality was concentrated in the poor for all countries (negative CI),
ith countries differing greatly in the extent. The dotted line shows
he points for which pre- and post-vaccination is the same. For all
ountries, post-vaccination results showed disparities that were
reater than before vaccination. Again, the extent of this differed
idely with some countries substantially below the dotted line.
ountries that were close to the line (more equitable benefit) were
hose with more equitable vaccination coverage (smaller dot).Fig. 3b shows the distribution of countries in terms of post-
accination mortality concentration (vertical axis) and vaccination
enefit (horizontal axis). For about one-third of countries, it
as estimated that vaccination would disproportionately benefit(1.06–1.77) 1.50 (1.08–1.81) 8 (6–11)
children in better off households (i.e., greater than 0 on the y-axis).
Countries with larger disparities in vaccination coverage (larger cir-
cles) are the most likely to be biased away from the poor. In contrast,
benefits are most equitable in countries where underlying rotavirus
burden is concentrated in the poor (darker) and yet vaccination is
relatively equitable (smaller).
3.1. Health cost of disparity
The health cost of vaccination disparity was estimated by mod-
eling a scenario where coverage in all quintiles was equal to that
of the highest wealth quintile. Results were reported as the esti-
mated rotavirus deaths averted per 1000 children, with current
coverage and ‘equitable’ coverage. Table 4 shows the estimated
deaths averted for the richest quintile and the poorest quintile
(current and equitable coverage), as well as the mortality cost of
disparities in coverage for the country as a whole. The health cost
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ffectiveness ratio ($/DALY) by wealth quintile for 8 high mortality countries.
f disparity for the poor in Chad, Nigeria, DRC, India and Niger
s substantial, where equitable coverage could improve mortal-
ty reduction among the poorest quintile by 656%, 460%, 96%, 90%
nd 89%, respectively. In contrast, the potential increase in impact
n the poorest quintile, due to more equitable vaccine coverage,
as less than 5% in Bangladesh, Uganda, and Ghana. Across the
5 countries, equitable coverage would increase mortality reduc-
ion benefits by 89% (range of 88–91% across mortality proxy
easures) among the poorest quintile and 38% overall (range of
7–40%).
.2. Geographic distribution
Geographic patterns of disparities were examined by modeling
xpected outcomes for India by state. Fig. 4 shows the estimated
ost-effectiveness ($/DALY averted) and vaccination benefit (DALYs
verted/1000 children) by state. Cost-effectiveness and benefits dif-
ered substantially among states, from over $250/DALY averted in
erala to less than $60/DALY averted in Madhya Pradesh. The states
ith the lowest CERs are those with high pre-vaccination mortality
larger circles). However, many of these same states also have the
owest percent reduction in rotavirus mortality (further to the left),
ue to low vaccination coverage (lighter color). If national rotavirus
accination were implemented on top of existing EPI coverage, then
he states with the most favorable cost-effectiveness ratios and
reatest burden would actually benefit the least.
. Discussion
Previous analyses have demonstrated substantial variability in
accination benefit and cost-effectiveness among countries based
n geography and economic status [1]. This disparity, in part, is the
ustification for GAVI investment in low-income countries where
enefits are greater and there is better value for money. These
nvestments are also based on rights and fairness principles that
hildren in low-income settings are entitled to these interven-
ions, even if households and national governments cannot afford
hem. The present analysis demonstrates that there are also strong
radients within countries that should be considered in decisions
egarding vaccination programs.Our analysis focuses on underlying disparities in vaccination
coverage and pre-vaccination rotavirus mortality risk, and their
impact on vaccination outcomes. Countries differed substantially
in their patterns of underlying disparities. In Fig. 1, countries with
longer lines had greater differences between quintiles in one or
both parameters. Some had greater disparities in vaccine cover-
age, represented by flatter lines, while others had more disparity
in mortality, the steeper lines.
Underlying disparities affect differences in estimated vaccina-
tion outcomes. Some countries, such as Bangladesh, Ghana, Uganda
and Lesotho, had relatively low disparities in both coverage and
mortality risk. This resulted in relatively equitable benefits of vacci-
nation. In countries with high disparities in coverage and mortality
risk (e.g., India, Pakistan and DRC) vaccination, in the absence of
efforts to reduce these disparities, would result in a further con-
centration of rotavirus mortality among the poor.
The answer to the question of whether rotavirus vaccination
will be equitable depends on both the context and the measure
of equity. One option is to consider the distribution of benefits by
wealth (or region) – is the estimated mortality reduction greater
or lower among poorer households? Based on the analysis of
Concentration Indices (Fig. 3), rotavirus vaccination would dispro-
portionately benefit the poor in two-thirds of the GAVI countries
considered. An alternative criterion is to ask whether vaccination
would increase or decrease the concentration of burden among
the poor or marginalized populations. Using this standard, vaccina-
tion is unlikely to be equitable unless programs specifically target
populations or regions with elevated mortality risk.
It is also important to note that vaccination investments in GAVI-
eligible countries target the global poor at a national level, making
vaccination available faster to children who would be unlikely
to receive it otherwise. However there is a great deal of overlap
in economic levels within populations in low and middle-income
countries. Countries such as India and Brazil have large economic
disparities that are obscured by national income level categories.
This means that many upper income children in low-income coun-
tries will receive GAVI-funded vaccines while low-income children
in middle-income countries will not. Additional analyses could
explore the cost-effectiveness and benefit of targeted efforts to
increase coverage among poorer or higher risk children in middle-
income countries.
4.1. Increasing cost-effectiveness and equity
This analysis suggests that the value for money of rotavirus vac-
cination could be substantially increased. Eliminating differences
in coverage between richest and poorest quintiles could increase
the number of deaths averted by 89% among the poorest quintile
and could increase the overall number of lives saved by 38%. This
is equivalent to increasing vaccine efficacy against severe rotavirus
infection from 57% to 79%. In countries with near-universal cover-
age or highly equitable coverage, there is little or no disparity in
benefits.
The analysis compares impact and cost-effectiveness with cur-
rent patterns of immunization and an equity scenario where poorer
children have the same coverage as those in the highest quin-
tile. While universal equitable coverage would reduce disparities,
an alternative would be to target accelerated introduction or
expanded coverage of high-risk children, based on geography or
other population characteristics. The cost-effectiveness and impact
estimates in Table 4 and Figs. 2 and 4 can be interpreted as the incre-
mental cost-effectiveness of introducing the vaccine into higher
risk populations first. The results suggest that it would be most
cost-effective to target these children first. Although few coun-
tries are considering sub-national introduction, this could be done
to target high-risk regions. In order to be most effective, these
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ortality for 30 GAVI-eligible countries.
egions would also need to have adequate levels of vaccine cov-
rage. Geographic targeting could also focus on more remote areas
here access to timely treatment of diarrhea is lower. For other
nfections with clear geographic hotspots (e.g., malaria and soil
ransmitted helminthes) this is a clear strategy for improving valuetavirus mortality, vaccination mortality reduction, and post-vaccination rotavirus
for money [30,31]. Although it can be more difficult to target chil-
dren based on socio-economic characteristics, there are examples
of programs designed to do this, such as conditional cash trans-
fer programs that target low-income communities and households
[32,33]. A related approach would be to target based on other risk
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actors such as nutritional status by coordinating with maternal
nd newborn nutrition programs. These targeting strategies would
ncrease the likelihood that investments go disproportionately to
he areas or children where they provide the greatest value for
oney. While these targeting strategies would create challenges,
he level of potential benefit (a 38% increase in mortality reduction)
s too great to ignore.
.2. Limitations
The current study is a preliminary assessment of the distribu-
ional effects and, as such, it has a number of limitations. First, no
ystematic data are available for directly estimating rotavirus mor-
ality or burden by wealth quintile or sub-national regions. As a
esult, we aggregated data on post-neonatal infant mortality and
ow weight-for-age as a proxy measure. It is important to note that
here is variability in estimated mortality disparities, depending on
hich proxy measure is used. For example, in Table 3 post-neonatal
ortality is highest in the second poorest quintile, rather than
he poorest. This may be the product of higher neonatal mortality
mong the poorest, differences in reporting biases or other factors.
his suggests that better proxy measures, at the level of quintiles
r individuals could provide more accurate estimates of disparities.
n addition, the analysis only explores one dimension of equity at a
ime (either socio-economic status or geographic location) without
xploring the interaction between them or whether other factors
uch as maternal education may explain both reduced vaccination
nd increased mortality risk. As a result, this may underestimate
he actual disparities in outcomes.The current analysis focuses on the differences in impact
cross socio-economic and geographic groups, however it does
ot include differences in the costs of reaching different pop-
lations or differences in the economic consequences of severes mortality, vaccination mortality reduction, and vaccination cost-effectiveness in
illness, such as medical costs. It is likely that it costs more to
reach higher risk children and more to increase coverage among
marginalized populations. In particular, there is little available
information on the incremental costs of increasing coverage for
economically or geographically marginalized children. Future stud-
ies should examine the costs of alternative strategies and their
resulting cost-effectiveness.
4.3. Other dimensions of disparities
The current model assumes equal vaccine efficacy across wealth
quintiles and states within a given country. Clinical trials have
demonstrated different levels of efficacy in countries with dif-
ferent income and mortality levels [21,23]. Among other factors,
these national level differences may be explained by variability
in exposure to other environmental enteric pathogens [21]. Given
the substantial within-country disparities in sanitation and water
access by region and wealth quintile, it is possible that there would
also be disparities in vaccine efficacy at the country level as well,
resulting in an underestimation of the actual inequities.
The current analysis assumed that vaccination timing is the
same across all wealth quintiles and regions, however this is likely
not the case. Patel et al. demonstrated substantial delays in immu-
nizations in 43 low-income countries [25]. It is quite possible that
delays are greater among children in the poorer quintiles. Delays
could lead to missing opportunities for preventing cases, and given
the current SAGE recommendations, could result in more poor chil-
dren not receiving the vaccine due to the age restrictions.
In addition, Atherly et al. [5] demonstrated that indirect protec-
tion through herd immunity might increase the cost-effectiveness
of vaccination and reduce the effects of delays or disparities in
coverage. If herd immunity occurs it could lead to high of rates
of coverage among better off children providing protection to poor
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hildren with lower rates of coverage, thus reducing the disparity
n benefit. Although the current analysis did not model the effect of
erd mortality or indirect protection, it suggests that their potential
mpact is likely to depend on the degree of social and geographic
ixing associated with the disparities in coverage. If economic and
ocial disparities in coverage are associated (as in the case of India),
hen indirect protection may be diminished. Even within states
r communities, spatial clustering of non-vaccinated children may
ead to reductions in indirect protection with poorer unvaccinated
hildren being less likely to be around vaccinated children and thus
ess likely to receive that indirect protection.
. Conclusions
The current study represents an initial effort to explore the
istributional effects of rotavirus vaccination at the sub-national
evel. The results demonstrate that rotavirus vaccination is most
ffective when targeted to low-income populations or geographic
egions. Programmatic or funding strategies that accelerate uptake
n high-risk subpopulations or regions would increase the cost-
ffectiveness and impact of national programs.
Earlier this year key international donors including the UK gov-
rnment and the Bill and Melinda Gates Foundation committed
illions of dollars to GAVI to expand and accelerate the introduction
f new childhood vaccines such as rotavirus. This occurred follow-
ng the announcement by GSK, one of the rotavirus manufacturers
hat they would reduce their price to $2.50 per dose for low-income
ountries. Both of these efforts greatly increase the number of chil-
ren in low-income countries who will receive the vaccine and the
umber of deaths that will be averted. However, the current study
uggests that these laudable efforts to benefit to the poorest popu-
ations and provide good value for money will fall short of their goal
ithout increased attention to the distributional effects on vacci-
ation. Both the cost-effectiveness of vaccination and its impact in
erms of deaths averted could be enhanced through greater atten-
ion to disparities in risk and in coverage.
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